EverHealth's Exosome Therapy
Stem cell-derived exosomes (extracellular vesicles) are an experimental biological therapeutic currently under investigation for their potential to modulate inflammation, facilitate cellular repair, and enhance immunological homeostasis. This encompasses the growing interest in exosome intravenous treatment and systemic delivery methods. Preliminary human studies, encompassing research in inflammatory lung illness, autoimmune disorders, and orthopedic recovery, indicate that exosome-based therapy may diminish systemic inflammatory biomarkers, including C-reactive protein (CRP), IL-6, and TNF-α, when provided systemically.
Cutting Edge Research
In a prospective human investigation of bone-marrow–derived exosomes, researchers saw significant drops in CRP, ferritin, and other inflammatory markers, as well as clinical improvement, after systemic distribution (Sengupta et al., Stem Cells Translational Medicine, 2020). Furthermore, several randomized human trials utilizing umbilical-cord-derived mesenchymal stem cell (UC-MSC) infusions where exosomes are posited to be critical mediators of therapeutic effects have exhibited statistically significant reductions in C-reactive protein (CRP) and circulating inflammatory cytokines in non-COVID inflammatory disease contexts, including autoimmune-related lung disease, degenerative joint disease, and chronic inflammatory conditions. (Chen et al., Journal of Translational Medicine, 2021; Lamo-Espinosa et al., Transplantation, 2016; Álvaro-Gracia et al., Annals of the Rheumatic Diseases, 2019).
Supporting Literature
These results are encouraging, but Exosome Therapy is still being studied in the United States and is not yet licensed by the FDA to diagnose, treat, cure, or prevent any disease. All use should only happen with the help of a doctor, and there should be strict restrictions on where the drugs come from, how clean they are, and how safe they are.
Human studies directly involving exosomes (systemic or parenteral use)
These include early-phase human studies and case-series data, showing inflammation signal improvement:
• Klinger et al. Extracellular vesicles in clinical medicine. Journal of Clinical Investigation. – Describes human and translational evidence of EV-mediated immunomodulation and cytokine reduction across inflammatory conditions.
• Fathi et al. Mesenchymal stem cell-derived exosomes: A new therapeutic approach. Stem Cell Research & Therapy. 2019. Summarizes pilot human data and mechanistic anti-inflammatory effects including cytokine suppression.
(Direct systemic non-COVID exosome human trials are still limited which is why the next category matters clinically and ethically.)
Human Trials
These are not just exosomes; they are the best data in humans that EV signaling can lower CRP and inflammatory markers in vivo:
• Álvaro-Gracia et al. A randomized, placebo-controlled trial of human umbilical cord mesenchymal stem cells in rheumatoid arthritis. The Annals of Rheumatic Diseases. 2019. Showed that levels of inflammatory cytokines including TNF-α and IL-6 went down.
• Chen et al. UC-MSC infusion for lung illness that causes inflammation. Journal of Translational Medicine. 2021. Demonstrated a decrease in systemic CRP and cytokine levels following MSC infusion.
• Lamo-Espinosa et al. MSC therapy for osteoarthritis makes cartilage better and lowers levels of inflammation. Transplantation. 2016. Showed less pain and less systemic inflammatory signals.
• Wang et al. Systemic MSC treatment in autoimmune and chronic inflammatory illness. Stem Cells International. – Meta-analysis validates the decrease in CRP and IL-6 across various situations.
These trials substantiate the biological feasibility that exosome-mediated immunomodulation might diminish inflammatory indicators in humans, hence advancing the evolving domain of Exosome Therapy.
Conclusion
Exosome treatment is still being studied and has not been approved by the FDA to diagnose, treat, cure, or prevent any illness. Any usage should only happen with a doctor’s supervision and with the right screening, permission, and safety checks in place.
At EverHealth, we only offer Exosome Therapy as an experimental service. We get it from suppliers that have been tested for good manufacturing practices (GMP-tested) and clinical validation, and we only give it to patients under the supervision of a doctor and with their informed agreement.
Important Notice About Safety and Regulations
• The FDA has not yet approved any exosome products for use in the United States for any medical purpose.
• Any use of exosomes as a therapeutic or disease-modifying agent is considered exploratory and usually needs IND/IRB review.
• At EverHealth, we only use exosomes as part of an experimental wellness-focused intervention, and we do it with thorough screening, documentation, and physician monitoring.
• We follow the strictest rules for sterility, product characterisation, traceability, and safety monitoring.
Experimental UC Exosome IV Protocol
We think that patients should have the most open information when looking into next-generation biologic therapies.
How might exosomes work?
Exosomes seem to change the way inflammatory signals work, lower oxidative stress, help keep endothelial cells stable, and encourage communication between cells that is important for healing. Initial human studies indicate possible advantages in modulating inflammatory biomarkers and facilitating tissue repair; however, a significant portion of this research is still in its nascent and exploratory stages. This encompasses systemic strategies, including exosome IV treatment and other experimental administration modalities.
There are some human studies that use:
- Extracellular vesicles from the umbilical cord
- Exosomes from bone marrow
- Perinatal EV products
These investigations indicate potential decreases in inflammation-related indicators such as CRP and IL-6, enhanced immunological equilibrium, and clinical enhancement in specific circumstances; nevertheless, larger trials are requisite.
What Conditions Are Being Researched?
Exosomes are being actively studied in:
• Systemic inflammatory states
• Post-infectious inflammation
• Orthopedic recovery and joint health
• Tissue repair and wound recovery
• Pulmonary inflammatory disease (including inhaled exosome research)
• Immune modulation
Again these are research-based uses, not approved medical treatments. Outcomes vary, and no therapeutic claims can be made at this time.
Exosomes vs. Stem Cells - What Does the Evidence Show?
There are more randomized human trials for IV umbilical-derived mesenchymal stem cells (UC-MSCs) showing reduction in inflammatory markers such as CRP and improvement in clinical outcomes particularly in respiratory inflammatory illness research than currently exist for IV exosomes. Exosomes Therapy data include smaller open-label cohorts and early human pilot studies, including nebulized delivery.
This means:
• Exosome therapy remains earlier-stage and exploratory
• Careful monitoring and conservative dosing approaches are appropriate
• Medical oversight is essential
Local vs. Systemic Administration
Local / Targeted Injection (Investigational Use)
Research is ongoing in:
• Tendinopathy
• Joint degeneration
• Soft-tissue injury recovery
• Post-procedural repair
Systemic / IV Administration (Investigational Use)
Early-stage human data suggest potential modulation of inflammatory biomarkers, but evidence remains limited and largely exploratory. This includes investigational exosome iv therapy protocols under physician oversight.
All systemic use is conducted only with:
• Physician screening
• Risk–benefit counseling
• Laboratory baseline and follow-up
• Safety monitoring and reporting
Standards for Safety, Sourcing, and Quality
We get our clinical-grade, lab-tested EV products from licensed GMP facilities that have:
• Identity check and verification (EV surface markers)
• Characterized nanoparticles
• Testing for sterility and mycoplasma
• Setting limits for endotoxins
• Controls for lot release and traceability
• Controls for storage and handling
Possible side effects include:
• Reactions related to the infusion
• Reactions to allergies
• Headache or flu-like symptoms
• Pain at the injection sites
• Possible effects on coagulation or immunological signaling
What to Expect at EverHealth
Every patient participates in a structured medical process:
Comprehensive Physician Consultation
- Medical history
- Risk profile review
- Medication assessment
- Expected goals and realistic expectations
Informed Consent & Screening
- Baseline inflammatory labs may be recommended
- Oncology, autoimmune, and infection status assessed
Procedure Oversight
- Delivered in a controlled setting
- Continuous monitoring
- Conservative dosing protocols
Follow-Up & Tracking
- Symptom and safety check-ins
- Optional biomarker analysis
- Adjustment or discontinuation if needed
Help in living a long time and looking young
HBOT is a potent tool for a complete longevity program because it affects oxygen delivery, stem cell activity, circulation, and inflammation. This is especially true when it is used with nutrition, fitness, sleep optimization, and treatment based on biomarkers.
Frequently Asked Questions
Is exosome therapy FDA-approved?
No. There are currently no FDA-approved exosome products. All use is investigational.
Are exosomes the same as stem cells?
No. Exosomes are cell-derived vesicles, not live stem cells.
Where do exosomes come from?
We work only with vetted GMP suppliers who provide validated sourcing and testing documentation.
Can exosome therapy cure disease?
No claims of cure or disease treatment can be made. Use is exploratory.
Who should not receive exosomes?
Generally excluded populations include:
• Active systemic infection
• Pregnancy or breastfeeding
• Active cancer under treatment (unless approved by oncology)
• Severe autoimmune flares
• Known allergy to product components
Experimental UC Exosome IV Prot…
Why Patients Choose EverHealth
• Physician-led care
• Ethical and transparent risk communication
• Evidence-anchored protocols
• Gold-standard sourcing quality
• Advanced biomarker monitoring
• Integration with your total longevity plan
We are proud to be at the forefront of responsible, safety-first regenerative medicine research access, ensuring that innovation is delivered with uncompromising medical standards.